From Analysis:
The debate discussed various metabolic interventions but lacked clear endpoints for clinical translation. Without validated biomarkers linking metabolic changes to neuronal survival, therapeutic development remains empirical rather than mechanism-guided. Source: Debate session sess_SDA-2026-04-02-gap-v2-5d0e3052 (Analysis: SDA-2026-04-02-gap-v2-5d0e3052)
The adenine nucleotide translocator (ANT), encoded by the SLC25A4 gene and also known as the ADP/ATP carrier 3 (AAC3), represents a critical component of mitochondrial bioenergetics that may serve as both a therapeutic target and biomarker in neurodegenerative diseases. Located in the inner mitochondrial membrane, ANT facilitates the obligatory exchange of cytosolic ADP for mitochondrial ATP, thereby coupling oxidative phosphorylation to cellular energy demands. This antiporter operates through a ping-pong mechanism involving two distinct conformational states: the cytoplasmic-facing c-state that binds ADP, and the matrix-facing m-state that binds ATP.
...No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["APP Full Length
Membrane Protein"]
B["BACE1 Beta-Secretase
Cleavage at beta-site"]
C["sAPPbeta + CTFbeta
C-terminal Fragment"]
D["Gamma-Secretase Complex
PSEN1/PSEN2"]
E["Abeta42 Peptide
Amyloidogenic Fragment"]
F["Abeta Oligomers
Toxic Aggregates"]
G["Amyloid Plaques
Extracellular Deposits"]
H["ADAM10 Alpha-Secretase
Non-amyloidogenic Path"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
A --> H
H -.->|"competes with BACE1"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for SLC25A4 from GTEx v10.
Based on the provided literature and the identified knowledge gap regarding metabolic biomarkers for neurodegeneration trials, I'll generate novel therapeutic hypotheses. The limited literature focuses on sex differences in dominantly inherited Alzheimer's disease, but I can extrapolate to broader metabolic biomarker applications.
I'll critically evaluate each hypothesis, identifying specific weaknesses and providing revised confidence scores. Since the literature provided is quite limited (focusing mainly on sex differences in dominantly inherited AD), I'll base my critique on this and general scientific principles.
Specific Weaknesses:
Based on the clinical landscape and druggability analysis, I'll assess the three most viable hypotheses:
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 💬 | Debate Round | $0.904 | ▲ 72.3% | market_dynamics | 2026-04-17 09:17 |
| 📊 | Score Update | $0.525 | ▲ 10.5% | market_dynamics | 2026-04-17 08:29 |
| 📄 | New Evidence | $0.475 | ▲ 7.6% | market_dynamics | 2026-04-17 08:09 |
| 💬 | Debate Round | $0.441 | ▲ 15.7% | market_dynamics | 2026-04-17 05:01 |
| 💬 | Debate Round | $0.382 | ▼ 27.2% | market_dynamics | 2026-04-17 04:46 |
| 📄 | New Evidence | $0.524 | ▼ 21.8% | market_dynamics | 2026-04-17 03:12 |
| 📊 | Score Update | $0.670 | ▲ 17.1% | market_dynamics | 2026-04-17 00:05 |
| 📄 | New Evidence | $0.572 | ▲ 17.3% | market_dynamics | 2026-04-16 22:21 |
| 📊 | Score Update | $0.488 | market_dynamics | 2026-04-16 20:47 |
No clinical trials data available
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
| Date | Signal Price | Score |
|---|---|---|
| 2026-04-17T09:10 | $0.610 | 0.493 |
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for SLC25A4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
h_ea5794f9["h-ea5794f9"] -->|targets| SLC16A1["SLC16A1"]
h_31980740["h-31980740"] -->|targets| SLC2A1["SLC2A1"]
h_2f3fa14b["h-2f3fa14b"] -->|targets| HMGCS2["HMGCS2"]
h_587ea473["h-587ea473"] -->|targets| CKB["CKB"]
h_f7da6372["h-f7da6372"] -->|targets| SLC25A4["SLC25A4"]
h_5b0ebb1f["h-5b0ebb1f"] -->|targets| CHKA["CHKA"]
h_b2706086["h-b2706086"] -->|targets| HPRT1["HPRT1"]
HMGCS2_1["HMGCS2"] -->|associated with| translational_neuroscienc["translational_neuroscience"]
CKB_2["CKB"] -->|associated with| translational_neuroscienc_3["translational_neuroscience"]
CHKA_4["CHKA"] -->|associated with| translational_neuroscienc_5["translational_neuroscience"]
SLC2A1_6["SLC2A1"] -->|associated with| translational_neuroscienc_7["translational_neuroscience"]
SLC16A1_8["SLC16A1"] -->|associated with| translational_neuroscienc_9["translational_neuroscience"]
style h_ea5794f9 fill:#4fc3f7,stroke:#333,color:#000
style SLC16A1 fill:#ce93d8,stroke:#333,color:#000
style h_31980740 fill:#4fc3f7,stroke:#333,color:#000
style SLC2A1 fill:#ce93d8,stroke:#333,color:#000
style h_2f3fa14b fill:#4fc3f7,stroke:#333,color:#000
style HMGCS2 fill:#ce93d8,stroke:#333,color:#000
style h_587ea473 fill:#4fc3f7,stroke:#333,color:#000
style CKB fill:#ce93d8,stroke:#333,color:#000
style h_f7da6372 fill:#4fc3f7,stroke:#333,color:#000
style SLC25A4 fill:#ce93d8,stroke:#333,color:#000
style h_5b0ebb1f fill:#4fc3f7,stroke:#333,color:#000
style CHKA fill:#ce93d8,stroke:#333,color:#000
style h_b2706086 fill:#4fc3f7,stroke:#333,color:#000
style HPRT1 fill:#ce93d8,stroke:#333,color:#000
style HMGCS2_1 fill:#ce93d8,stroke:#333,color:#000
style translational_neuroscienc fill:#ef5350,stroke:#333,color:#000
style CKB_2 fill:#ce93d8,stroke:#333,color:#000
style translational_neuroscienc_3 fill:#ef5350,stroke:#333,color:#000
style CHKA_4 fill:#ce93d8,stroke:#333,color:#000
style translational_neuroscienc_5 fill:#ef5350,stroke:#333,color:#000
style SLC2A1_6 fill:#ce93d8,stroke:#333,color:#000
style translational_neuroscienc_7 fill:#ef5350,stroke:#333,color:#000
style SLC16A1_8 fill:#ce93d8,stroke:#333,color:#000
style translational_neuroscienc_9 fill:#ef5350,stroke:#333,color:#000
translational neuroscience | 2026-04-04 | completed
No comments yet. Be the first to comment!